Published in J Clin Invest on September 01, 1995
Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res (2001) 3.26
Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest (2005) 1.89
Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol (2008) 1.80
Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation (2013) 1.76
Disorders of lung matrix remodeling. J Clin Invest (2004) 1.69
Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest (1997) 1.49
Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther (2010) 1.46
Focal adhesion kinase (FAK)-related non-kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK-dependent manner. J Biol Chem (2008) 1.42
The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax (2007) 1.41
PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest (2000) 1.32
Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxid Redox Signal (2008) 1.31
Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol (2010) 1.27
Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J Clin Invest (1996) 1.25
Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter. Am J Physiol Lung Cell Mol Physiol (2007) 1.22
A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice. Am J Pathol (2000) 1.22
Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis. Am J Respir Cell Mol Biol (2007) 1.20
Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors. J Immunol (2008) 1.11
The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol (2004) 1.08
Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J (2011) 1.07
Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice. Am J Pathol (2009) 1.06
Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis. Am J Respir Cell Mol Biol (2012) 1.06
Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci U S A (2002) 1.04
FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis. Am J Pathol (2013) 1.04
Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J Biol Chem (2008) 1.03
PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury. J Pathol (2012) 1.02
Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood (2005) 1.01
TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice. J Clin Invest (2014) 0.98
The inflammatory actions of coagulant and fibrinolytic proteases in disease. Mediators Inflamm (2015) 0.93
Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system. Am J Physiol Lung Cell Mol Physiol (2011) 0.92
Transforming growth factor-β1 induces expression of human coagulation factor XII via Smad3 and JNK signaling pathways in human lung fibroblasts. J Biol Chem (2010) 0.90
Increased plasminogen activator inhibitor-1 in keloid fibroblasts may account for their elevated collagen accumulation in fibrin gel cultures. Am J Pathol (2003) 0.90
Fibrin-induced skin fibrosis in mice deficient in tissue plasminogen activator. Am J Pathol (2005) 0.89
The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis. Am J Pathol (1997) 0.89
Using mouse genomics to understand idiopathic interstitial fibrosis. Proc Am Thorac Soc (2007) 0.85
The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev (2015) 0.85
Role of the urokinase-fibrinolytic system in epithelial-mesenchymal transition during lung injury. Am J Pathol (2014) 0.83
Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis. Redox Biol (2015) 0.83
Sphingolipid regulation of tissue fibrosis. Open Rheumatol J (2012) 0.82
Urokinase in rheumatoid arthritis: causal or coincidental? Ann Rheum Dis (1997) 0.81
Regulation of Alveolar Procoagulant Activity and Permeability in Direct Acute Lung Injury by Lung Epithelial Tissue Factor. Am J Respir Cell Mol Biol (2015) 0.81
Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma. Clin Exp Immunol (2005) 0.80
Plasminogen activator inhibitor type 1 up-regulation is associated with skeletal muscle atrophy and associated fibrosis. Am J Pathol (2009) 0.80
Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants. Histochem Cell Biol (2007) 0.80
Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-β-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts. PLoS One (2016) 0.77
Asbestos induces tissue factor in Beas-2B human lung bronchial epithelial cells in vitro. Lung (2004) 0.77
Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts. Lab Invest (2014) 0.75
Kinetics of lung tissue factor expression and procoagulant activity in bleomycin induced acute lung injury. Clin Transl Med (2015) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem (1986) 10.00
Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res (1985) 7.67
Molecular and cellular biology of intermediate filaments. Annu Rev Biochem (1988) 5.48
Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol (1989) 5.41
Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A (1991) 4.61
Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol (1989) 4.57
The plasminogen activator/plasmin system. J Clin Invest (1991) 4.20
Production of mRNA in Chinese hamster cells: relationship of the rate of synthesis to the cytoplasmic concentration of nine specific mRNA sequences. Cell (1979) 3.67
Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J Biol Chem (1987) 3.25
An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis (1989) 3.12
Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res (1981) 3.00
Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med (1989) 2.99
Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol (1987) 2.63
The structural biology of expression and function of tissue factor. Thromb Haemost (1991) 2.28
Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol (1993) 2.27
Pathobiology of pulmonary fibrosis. Am J Physiol (1990) 2.11
Regulation of extravascular coagulation by microvascular permeability. Science (1985) 2.11
Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem (1987) 2.05
Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice. J Pharmacol Exp Ther (1988) 2.01
Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J (1987) 1.98
Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem (1988) 1.93
Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest (1989) 1.88
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest (1991) 1.85
Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A (1992) 1.76
Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation. J Clin Invest (1984) 1.72
Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest (1986) 1.72
The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis (1983) 1.71
Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett (1987) 1.66
Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Anal Biochem (1984) 1.59
Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest (1991) 1.59
Unraveling pulmonary fibrosis: the bleomycin model. Lab Invest (1984) 1.56
Morphologic and biochemical study of pulmonary changes induced by bleomycin in mice. Lab Invest (1976) 1.54
Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol (1993) 1.52
The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Mol Cell Biol (1990) 1.49
Murine tissue factor gene expression in vivo. Tissue and cell specificity and regulation by lipopolysaccharide. Am J Pathol (1993) 1.45
Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis (1986) 1.33
Plasminogen activator activity in cultures from human tissues. An immunological and histochemical study. J Clin Invest (1969) 1.33
Fibronectin. A versatile matrix protein with roles in thoracic development, repair and infection. Chest (1992) 1.30
Profiles of steady state levels of messenger RNAs coding for type I procollagen, elastin, and fibronectin in hamster lungs undergoing bleomycin-induced interstitial pulmonary fibrosis. J Clin Invest (1985) 1.30
Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis (1989) 1.13
Immunohistochemical identification of cell types in normal and in bleomycin-induced fibrotic rat lung. Cellular origins of interstitial cells. Am Rev Respir Dis (1984) 1.05
Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage. J Clin Invest (1989) 1.04
Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition. Am J Pathol (1989) 1.01
Tissue plasminogen activator mRNA in murine tissues. FEBS Lett (1988) 1.01
Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension. Circulation (1992) 1.00
Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin. Biochim Biophys Acta (1991) 1.00
Tissue factor procoagulant expression by rat alveolar epithelial cells. Am J Respir Cell Mol Biol (1992) 0.97
Local abnormalities of coagulation and fibrinolysis and alveolar fibrin deposition in sheep with oleic acid-induced lung injury. Am Rev Respir Dis (1988) 0.93
Isolation of vasoactive peptides from human fibrin and fibrinogen degraded by plasmin. Thromb Res (1978) 0.91
Alteration of bronchoalveolar lavage cell populations following bleomycin treatment in mice. Toxicol Appl Pharmacol (1989) 0.91
Regulation of the procoagulant activity within the bronchoalveolar compartment of normal human lung. Am Rev Respir Dis (1988) 0.89
Intratracheal versus intravenous administration of bleomycin in mice: acute effects. Toxicol Appl Pharmacol (1986) 0.87
Tissue fibrin deposition during acute lung injury in rabbits and its relationship to local expression of procoagulant and fibrinolytic activities. Am Rev Respir Dis (1987) 0.86
Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the beta chain. J Clin Invest (1992) 0.86
Tissue factor in bronchoalveolar lavage fluids. Evidence for an alveolar macrophage source. Am Rev Respir Dis (1985) 0.86
Improved medium for extraction of plasminogen activator from tissue. Prep Biochem (1982) 0.85
Role of enzymes mediating thrombosis and thrombolysis in lung disease. Chest (1988) 0.80
The distribution of procoagulant and plasminogen activator activities among density fractions of normal rabbit alveolar macrophages. Am Rev Respir Dis (1986) 0.78
LPS induction of gene expression in human monocytes. Cell Signal (2001) 7.61
An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem (1994) 6.31
Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol (2000) 3.96
Escherichia coli hemolysin may damage target cell membranes by generating transmembrane pores. Infect Immun (1986) 3.94
Secretion of haemolysin by Escherichia coli. Curr Top Microbiol Immunol (1986) 3.21
Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol (1989) 3.01
Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci U S A (1977) 2.83
Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med (2000) 2.79
Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. J Biol Chem (1997) 2.73
AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation (2000) 2.57
Role of tissue factor in embryonic blood vessel development. Nature (1996) 2.54
Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem (1991) 2.52
The structural biology of expression and function of tissue factor. Thromb Haemost (1991) 2.28
Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem (1985) 2.23
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem (1984) 2.22
Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol (1996) 2.21
Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A (1983) 2.20
Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest (1998) 2.19
Endobronchial metastases due to colorectal carcinoma. Chest (1989) 2.13
Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem (1988) 2.04
The carboxy-terminal region of haemolysin 2001 is required for secretion of the toxin from Escherichia coli. Mol Gen Genet (1986) 2.02
Characterisation of HlyC and mechanism of activation and secretion of haemolysin from E. coli 2001. FEBS Lett (1985) 2.01
HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene (2006) 1.94
Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem (1988) 1.93
Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem (1989) 1.92
Genetical and functional organisation of the Escherichia coli haemolysin determinant 2001. Mol Gen Genet (1985) 1.92
Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med (1997) 1.92
Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J Clin Invest (1998) 1.89
Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest (1986) 1.89
Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A (1986) 1.85
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest (1991) 1.85
Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. J Immunol (1997) 1.82
The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. Am J Respir Crit Care Med (1999) 1.80
Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol (1982) 1.77
Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A (1992) 1.76
Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest (1982) 1.76
Functional characterization of a cloned haemolysin determinant from E. coli of human origin, encoding information for the secretion of a 107K polypeptide. Mol Gen Genet (1984) 1.75
The treatment of endobronchial stenosis using balloon catheter dilatation. Chest (1988) 1.73
Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost (2008) 1.70
Role of cardiac myocyte tissue factor in heart hemostasis. J Thromb Haemost (2007) 1.68
Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest (1996) 1.65
Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci U S A (1988) 1.64
Secretion of a 107 K dalton polypeptide into the medium from a haemolytic E. coli K12 strain. Mol Gen Genet (1984) 1.62
Primary pulmonary hypertension. The risk and benefit of lung biopsy. Circulation (1989) 1.61
Escherichia coli haemolysin forms voltage-dependent ion channels in lipid membranes. Biochim Biophys Acta (1987) 1.61
A novel C-terminal signal sequence targets Escherichia coli haemolysin directly to the medium. J Cell Sci Suppl (1989) 1.60
Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem (1999) 1.60
Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Anal Biochem (1984) 1.59
Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med (1981) 1.58
Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci U S A (1998) 1.57
Glycosyl-phosphatidylinositol-anchored or integral membrane forms of CD14 mediate identical cellular responses to endotoxin. Proc Natl Acad Sci U S A (1993) 1.55
Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem (1996) 1.55
Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem (1996) 1.55
Novel mouse hemostasis model for real-time determination of bleeding time and hemostatic plug composition. J Thromb Haemost (2015) 1.54
The C-terminal, 23 kDa peptide of E. coli haemolysin 2001 contains all the information necessary for its secretion by the haemolysin (Hly) export machinery. FEBS Lett (1986) 1.54
Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. J Clin Invest (1980) 1.53
Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc Natl Acad Sci U S A (1999) 1.53
Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol (1993) 1.52
Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest (1984) 1.50
Bronchial hyperreactivity in chronic obstructive bronchitis. Am Rev Respir Dis (1982) 1.50
Risk of complications during intravenous heparin therapy. West J Med (1982) 1.50
Current early results of pulmonary thromboendarterectomy for chronic pulmonary embolism. Eur J Cardiothorac Surg (1990) 1.49
Type 1 plasminogen activator inhibitor. Prog Hemost Thromb (1989) 1.49
Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol (2000) 1.48
Cellular immune response in coccidioidomycosis. Cell Immunol (1975) 1.46
Murine CD14 gene expression in vivo: extramyeloid synthesis and regulation by lipopolysaccharide. J Exp Med (1995) 1.46
Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice. J Thromb Haemost (2009) 1.46
The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci U S A (1985) 1.46
Percutaneous pulmonary endoarterial biopsy in an experimental model of pulmonary hypertension. Chest (1998) 1.46
Murine tissue factor gene expression in vivo. Tissue and cell specificity and regulation by lipopolysaccharide. Am J Pathol (1993) 1.45
Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol (1995) 1.44
Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci U S A (1998) 1.44
Successful surgical intervention in severe chronic thromboembolic pulmonary hypertension. Chest (1973) 1.44
Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide. Mol Cell Biol (1991) 1.44
Bronchoscopy and transbronchial biopsy in evaluation of patients with suspected active tuberculosis. Am J Med (1981) 1.43
Lipopolysaccharide induction of tissue factor gene expression in monocytic cells is mediated by binding of c-Rel/p65 heterodimers to a kappa B-like site. Mol Cell Biol (1994) 1.42
Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest (2001) 1.41
Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period. J Thorac Cardiovasc Surg (1993) 1.41
Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med (1999) 1.40
Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation (2001) 1.39
Clinical conference on management dilemmas. Pulmonary vasculopathy and recurrent pneumothoraces. Chest (1996) 1.38
The role of integrins in the malignant phenotype of gliomas. Front Biosci (1999) 1.37
Shear stress induction of the tissue factor gene. J Clin Invest (1997) 1.35
Results of a comprehensive rehabilitation program. Physiologic and functional effects on patients with chronic obstructive pulmonary disease. Arch Intern Med (1980) 1.33
A set of inducible genes expressed by activated human monocytic and endothelial cells contain kappa B-like sites that specifically bind c-Rel-p65 heterodimers. J Biol Chem (1994) 1.33
Large vessel pulmonary arteritis mimicking chronic thromboembolic disease. Am J Respir Crit Care Med (1995) 1.33
Identification with monoclonal antibodies of hemolysin produced by clinical isolates of Escherichia coli. J Clin Microbiol (1987) 1.32
Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction. Proc Natl Acad Sci U S A (2002) 1.31
Identification of polypeptides required for the export of haemolysin 2001 from E. coli. Mol Gen Genet (1985) 1.31
Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem (1996) 1.31
Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells. J Biol Chem (1998) 1.31
Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost (2012) 1.29
Air travel hypoxemia with chronic obstructive pulmonary disease. Ann Intern Med (1984) 1.29
Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest (1996) 1.29
Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood (1998) 1.29
Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis. J Thromb Haemost (2006) 1.28
RelB modulation of IkappaBalpha stability as a mechanism of transcription suppression of interleukin-1alpha (IL-1alpha), IL-1beta, and tumor necrosis factor alpha in fibroblasts. Mol Cell Biol (1999) 1.28
Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res (1999) 1.28